CHADD’s CEO reported pharmaceutical support of 26.6%, or $1,174,626, as of June 30, 2009, and described disclosures begun in 2008 and 2009. The same article reports NAMI’s executive director saying about 50% of NAMI’s annual budget came from pharmaceutical companies and that NAMI began listing grants of at least $5,000 in 2009.
E. Clarke Ross, DPA, CEO for CHADD, said that total pharmaceutical donation support of CHADD as of June 30, 2009 was 26.6% ($1,174,626). CHADD’s board established a ceiling of 30% from industry.
CHADD’s CEO reported pharmaceutical support of 26.6%, or $1,174,626, as of June 30, 2009, and described disclosures begun in 2008 and 2009. The same article reports NAMI’s executive director saying about 50% of NAMI’s annual budget came from pharmaceutical companies and that NAMI began listing grants of at least $5,000 in 2009. Accessible secondary corroboration containing self-reported organizational figures.